Marvelle Sullivan Berchtold
Founder of MCo
New York, New York
Overview
Work Experience
Founder & CEO
2019 - Current
https://www.marvelleco.com/
Independent Trustee, Baron Funds
2020
Baron Capital Group is a research-driven, long-term equity investment firm focused on delivering growth equity investment solutions.
Board Member, London School of Economics North American Advisory Board
2018
Managing Director
2017 - 2019
While at JPM, Marvelle's almost exclusive focus was on forging the healthcare initiative among Amazon, Berkshire Hathaway and JPM, which resulted in the establishment of Haven
Morgan Health is the healthcare investment arm of JPMorgan Chase.
Board Member, GSK Consumer Healthcare
2015 - 2017
Global Head of M&A
2013 - 2017
As Global Head of M&A, Marvelle was responsible for leading the M&A strategy development and implementation of the Novartis Group. Since joining Novartis, she has represented the company in over $100 billion of transactions. In March 2015, she became a member of the Board of Directors of GSK Consumer Healthcare, a joint venture between GSK and Novartis. Her recent, major transactions comprised the "Novartis Portfolio Transformation" series of transactions, were all announced within one year of each other and include: - Acquisition of GSK's Oncology portfolio for $16 billion - Sale of Novartis Vaccines to GSK for $5.3 billion plus milestones and royalties - Establishment of the Novartis-GSK Consumer Healthcare joint venture - Sale of Novartis Animal Health to Lilly for $5.4 billion - Sale of Novartis Diagnostics (Blood Transfusion) to Grifols for $1.7 billion - Sale of Novartis Influenza Vaccines Unit to CSL for $275 million
Head of M&A Execution
2013 - 2013
Head of Legal M&A
2009 - 2012
Associate
2005 - 2008